Serum and Urine Level of IP-10 in Patients with HCV infection Based on Clinical and Virological Markers

Background and aims: ip-10 molecule is a new biomarker to predict response to treatment in chronic hcv infection. also urine ip-10 has been suggested as a biomarker in other infections. but already, it has low data in urine as well as serum level of ip-10 for hcv infection. the aim of this study was to assess urine and serum level of ip-10 in patients with type 1 and 3a hcv infection. materials and methods: in this case-control study, 105 patients with hcv infection were involved in three 35 people groups. blood and urine sample of all patients was collected to determine ip-10 level. finally, data analysis was reported using spss, mean statistics analysis and t test. results: the age mean was 41.6+-11.2 ranging 21-68. urine and serum level of ip-10 in patient group was significantly higher than control (p=0.001). serum level of ip-10 based on hcv genotype was higher significantly in genotype 1a than 3a (p=0.001) but there was no significant difference of urine ip-10 level between genotypes 1a and 3a. conclusions: the results show ip-10 is a proper marker to determine the prognosis of fibrosis and progress liver inflammation and on the other hand, the prediction of response to treatment differs in various genotypes of hcv infection.